Vectura’s range of pre-metered foil blister DPIs has been developed to meet patients’ needs in inhalation therapy for asthma and COPD. The devices are low cost and easy to use, yet they meet challenging technical and regulatory requirements. The core technology and IP used in GyroHaler® has also been incorporated in a family of devices aimed at meeting future product development and partnering opportunities.
GyroHaler® is a cost-effective, multi-unit dose dry powder inhaler designed to deliver locally acting drugs to the lungs. The device has a Red Dot design award and is approved and marketed in Europe and other territories as Sandoz’s AirFluSal® Forspiro® (Forspiro® is the name Sandoz gave to Vectura’s GyroHaler® device). GyroHaler®, is suitable for the delivery of a wide range of respiratory drugs and offers:
The lever-operated DPI is based on the proven GyroHaler® platform and offers:
The open-inhale-close DPI is a development programme that is aimed at developing the simplest possible user interface in addition to incorporating technology and IP used in the GyroHaler® and lever-operated DPI. The open-inhale-close DPI offers:
verixo® is a high performance, reusable device. It uses the same foil blister material and filling technology as GyroHaler® for optimum dose consistency and protection, and is capable of delivering high doses of drug with high lung delivery efficiency. The device offers:
Multi-dose DPI developed by Skyepharma has been approved for use in the US, as well as in over 30 other countries, with commercial-scale assets available. SkyeHaler™ has a differentiated and competitive image with patented elements offering proprietary protection for branded NCEs and premium generics. It also has the flexibility to deliver a range of formulations as a platform device and offers: